Share ownership Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:52 2026-01-16 am EST			5-day change	1st Jan Change
115.60 ^CHF	+0.98%		+1.37%	+5.47%

Jan. 18	Novartis Lands US FDA Breakthrough Therapy Classification for Ianalumab in Sjögren's Disease	MT
Jan. 16	Novartis Ianalumab Receives Fda Breakthrough Therapy Designation for Sjogren's Disease	CI

Share class: Novartis AG

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,189,930,497	1,909,335,641 ( 87.19 %)	214,841,249 ( 9.81 %)	87.19 %

Major shareholders: Novartis AG

Name	Equities	%	Valuation
NOVARTIS AG 7.036 %	148,621,654	7.036 %	20 594 M CHF
UBS Asset Management Switzerland AG 6.609 %	139,602,467	6.609 %	19 344 M CHF
Sandoz Family Foundation 4.25 %	89,787,150	4.25 %	12 442 M CHF
Sjunde AP-fonden 0.1596 %	3,370,792	0.1596 %	467 M CHF
State Street Global Advisors Ltd. 0.1456 %	3,075,341	0.1456 %	426 M CHF
Baloise Asset Management AG 0.1092 %	2,307,706	0.1092 %	320 M CHF
DWS CH AG 0.1029 %	2,172,701	0.1029 %	301 M CHF
Basellandschaftliche Kantonalbank (Investment Management) 0.0824 %	1,740,762	0.0824 %	241 M CHF
Nordea Investment Management AB 0.0775 %	1,637,402	0.0775 %	227 M CHF
Berner Kantonalbank AG (Investment Management) 0.0761 %	1,607,757	0.0761 %	223 M CHF
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Dodge & Cox 0.5011 %	10,585,145	0.5011 %	1 459 M CHF
PRIMECAP Management Co. 0.4422 %	9,341,854	0.4422 %	1 288 M CHF
DFA Australia Ltd. 0.3933 %	8,307,967	0.3933 %	1 145 M CHF
Eaton Vance Management 0.3659 %	7,728,873	0.3659 %	1 066 M CHF
Fisher Asset Management LLC 0.3427 %	7,239,366	0.3427 %	998 M CHF
Loomis, Sayles & Co. LP 0.2682 %	5,664,911	0.2682 %	781 M CHF
U.S. Trust Company of Delaware 0.218 %	4,605,878	0.218 %	635 M CHF
Fiduciary Trust Company International 0.1922 %	4,059,319	0.1922 %	560 M CHF
Wells Fargo Bank NA 0.1668 %	3,523,096	0.1668 %	486 M CHF
Goldman Sachs Wealth Services LP 0.1396 %	2,949,647	0.1396 %	407 M CHF
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
LUKB Expert Fondsleitung AG -	123,244	-	17 M CHF
Fnb Stockbroking & Portfolio Management Pty Ltd. (Invt Mgmt) -	6,000	-	832 619 CHF
Columbia Threadneedle Management Ltd. -	1,019	-	141 406 CHF
Melville Douglas Investment Management (Pty) Ltd. -	415	-	57 589 CHF

Breakdown by shareholder type

Institutional	14.81%
Novartis AG	7.04%
Other	5.18%
State Street Corp.	0.07%
Individuals	0.04%
SEI Investments Co.	0.03%
First Financial Bankshares, Inc.	0.01%
Unknown	72.81%

Based on 1000 largest holdings

Geographical origin of shareholders

Switzerland	19.08%
United States	5.67%
Australia	0.41%
United Kingdom	0.36%
Sweden	0.25%
Canada	0.2%
Ireland	0.15%
Germany	0.13%
Belgium	0.11%
Italy	0.11%
Luxembourg	0.1%
France	0.09%
Liechtenstein	0.07%
Norway	0.07%
Netherlands	0.07%
Spain	0.06%
Finland	0.05%
Austria	0.04%
Individuals	0.04%
Denmark	0.04%
Japan	0.02%
Cyprus	0.01%
Hong Kong	0.01%
South Africa	0.01%

Based on 1000 largest holdings

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (29.3%); - immunology (18.5%); - cardiovascular, renal and metabolic diseases (17%); - neuroscience (9.4%). The remaining net sales (25.8%) are from contract manufacturing of pharmaceutical products. At the end of 2024, Novartis AG had over 30 production sites worldwide. Net sales are distributed geographically as follows: Europe (30.9%), the United States (42%), Asia/Africa/Australasia (20%), Canada and Latin America (7.1%).

Employees

75,883

Sector

Pharmaceuticals

Calendar

Feb. 03 - Q4 2025 Earnings Release

More about the company